CHART: Congestive cardiac failure in hospitals an Australian review of treatment

Heart Lung and Circulation

Volumn 12, Issue 2, 2003, Pages 94-102

  Wlodarczyk, John H ^a   Keogh, Anne ^b   Smith, Karina ^c   McCosker, Cate ^b  

^a John Wlodarczyk Consulting Services   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

ACE inhibitors; Beta blockers; Heart failure; Hospitalisation; Pharmacotherapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; METOPROLOL; NITRATE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL;

ADULT; AGE; AGED; ASTHMA; AUSTRALIA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TEACHING HOSPITAL;

EID: 0142124356     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2003.00197.x     Document Type: Article

References (31)

1. Hillis GS, Al-Mohammed Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996; 76: 427-9.
2. Blyth FM, Lazarus R, Ross D, Price M, Cheuk G, Leeder SR. Burden and outcomes of hospitalization for congestive heart failure. Med. J. Aust. 1997; 167: 67-70.
3. Krum H, Tonkin AM, Currie R, Djundjek R, Johnston CI. Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med. J. Aust. 2001; 174: 439-44.
4. Australian Institute of Health and Welfare National Hospital Morbidity Database [Internet]. Australian Institute of Health and Welfare, Canberra, Australia [updated 16 May 2003; cited May 2002]. Available from: http://www.aihw.gov.au/cognos/cgi-bin.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N. Engl. J. Med. 1992; 327: 685-91.
7. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 1991; 325: 303-10.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429-35.
9. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996; 334: 1349-55.
10. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
11. MERIT Investigators. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
12. RALES Investigators. Effectivenes of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 1996; 78: 902-7.
13. Pitt B, Zannad F, Remme W et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709-17.
14. Andersson F, Cline C, Ryden-Bergsten T, Erhardt L. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. Pharmacoeconomics 1999; 15: 535-50.
15. Ferreira A, Bettencourt P, Cortez M, Araujp JP, Cerqueira-Gomes M. Angiotensin-converting enzyme inhibitors in heart failure: physician's prescribing behavior. J. Cardiac Failure 1997; 3: 295-302.
16. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL Jr. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am. J. Cardiol. 1998; 82: 465-9.
17. Farnsworth A. Angiotensin-converting enzyme inhibitors in heart failure; target dose prescription in elderly patients. Letters to the editor. Age and Ageing 1998; 27: 653-4.
18. Lowe JM, Candlish PM, Henry DA, Wlodarczyk JH, Heller RF, Fletcher PJ. Management and outcomes of congestive heart failure: a prospective study of hospitalized patients. Med. J. Aust. 1998; 168: 115-18.
19. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am. J. Cardiol. 1996; 77: 832-8.
20. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin. Cardiol. 1998; 21: 103-8.
21. American College of Cardiology/American Heart Association. Guidelines for the evaluation and management of heart failure. Report of the Amercian College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764-84.
22. Anonymous. Consensus recommendations for the management of chronic heart failure. Am. J. Cardiol. 1999; 83: 1A-38A.
23. European Society of Cardiology. Task force of the Working Group on heart failure of the European Society of Cardiology. The treatment of heart failure. Eur. Heart J. 1997; 18: 736-53.
24. McMurray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur. J. Heart Failure 2001; 3: 495-502.
25. Krum H. Guidelines for management of patients with chronic heart failure in Australia. Med. J. Aust. 2001; 174: 459-66.
26. Keogh A, Smith K, McCosker C. Cardiac failure in hospitals. An Australian review of treatment ('CHART' pilot study). 48th Annual Scientific Meeting of CSANZ. Heart, Lung, Circulation 2000; 9: A137 (Abstract).
27. Tang WHW, Vagelos RH, Yee Y-G, Benedict C, Willson K, Liss CL, LaBelle P. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J. Am. Coll. Cardiol. 2002; 39: 70-78.
28. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-18.
29. Nicklas JM, Cohn JN, Pitt B. What does ATLAS really tell us about 'high' dose angiotensin-converting enzyme inhibition in heart failure? J. Cardiac Failure 2000; 6: 165-8.
30. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J. Heart Lung Transplant. 2002; 21: 1290-95.
31. Hobbs FDR. Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br. J. General Prac. 2000; 50: 735-42.